Pregnancy registry
Prospective, Registry-Based Observational Cohort Study of Zavegepant Safety in Pregnancy
United States
EU PAS number:
EUPAS1000000335
First published:
05/11/2024
StudyPlanned
A Post-marketing, Observational, Descriptive Study to Assess the Risk Associated With Pregnancy, the Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Individuals Exposed to Omaveloxolone During Pregnancy and/or Lactation
United States
EU PAS number:
EUPAS1000000327
First published:
14/02/2025
StudyPlanned
Nested case-control study evaluating effectiveness of immunization of girls and women of childbearing potential with GARDASIL(TM)/GARDASIL(TM) 9 against juvenile-onset recurrent respiratory papillomatosis (JoRRP) in Sweden, Denmark, and Norway (V503-095)
Denmark
Norway
Sweden
EU PAS number:
EUPAS1000000286
First published:
17/12/2024
StudyOngoing
ADEPT: feasibility of estimating the risk of adverse pregnancy, neonatal and child outcomes following either in utero ASM exposure through the mother, or peri-conceptional ASM exposure through the father
Finland
France
Italy
Netherlands
Norway
Spain
United Kingdom
EU PAS number:
EUPAS1000000246
First published:
13/03/2025
StudyOngoing
A Post-Marketing Safety Study using a Pregnancy Registry to Evaluate the Safety of Respiratory Syncytial Virus Vaccine (ABRYSVO™) Exposure During Pregnancy (C3671041)
United States
EU PAS number:
EUPAS1000000179
First published:
29/10/2024
StudyPlanned
Antipsychotics in pregnancy and the risk of adverse pregnancy outcomes - a nationwide study
Norway
EU PAS number:
EUPAS1000000134
First published:
28/02/2025
StudyPlanned
QUVIVIQ® Pregnancy Registry (ID-078A403)
Canada
France
Germany
Italy
Spain
United Kingdom
United States
EU PAS number:
EUPAS1000000033
First published:
13/12/2024
StudyOngoing
Vedolizumab-5001: Organization of Teratology Information Specialists (OTIS) Vedolizumab Pregnancy Exposure Registry
Canada
United States
EU PAS number:
EUPAS11681
First published:
21/11/2024
StudyFinalised
Strengthening Use of Real-World Data in Medicines Development: Metadata for Data Discoverability and Study Replicability (MINERVA)
Austria
Belgium
Czechia
Denmark
Estonia
France
Germany
Italy
Netherlands
Slovenia
Spain
Sweden
Switzerland
United Kingdom
EU PAS number:
EUPAS39322
First published:
16/12/2024
StudyFinalised
The Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (Gilenya Pregnancy Registry)
Argentina
Australia
Austria
Belgium
Canada
Cyprus
Czechia
Denmark
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Lebanon
Mexico
Netherlands
Poland
Portugal
Russian Federation
Saudi Arabia
Spain
Sweden
Switzerland
United Arab Emirates
United Kingdom
United States
EU PAS number:
EUPAS2569
First published:
10/02/2025
StudyOngoing